JARDIANCE
Jardiance (empagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage type 2 diabetes mellitus and heart failure in adults. It is indicated to improve glycemic control as an adjunct to diet and exercise, and to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease. Additionally, the medication is approved to reduce the risk of cardiovascular death and hospitalization in adults with heart failure. It is not recommended for patients with type 1 diabetes or for glycemic control in patients with an eGFR less than 30 mL/min/1.73 m².
How JARDIANCE Works
Empagliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2), which is the primary transporter responsible for reabsorbing glucose from the glomerular filtrate back into the blood circulation. By blocking this transporter, the drug reduces renal reabsorption of filtered glucose and increases urinary glucose excretion. The medication also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule of the kidney. These physiological changes may lower both the pre-and afterload of the heart and downregulate sympathetic activity.
Details
- Status
- Prescription
- First Approved
- 2014-08-01
- Routes
- ORAL
- Dosage Forms
- TABLET
JARDIANCE Approval History
What JARDIANCE Treats
3 indicationsJARDIANCE is approved for 3 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Type 2 Diabetes
- Heart Failure
- Chronic Kidney Disease
JARDIANCE Target & Pathway
ProTarget
A transporter in the kidney that reabsorbs glucose back into the bloodstream. Blocking SGLT2 causes excess glucose to be excreted in urine, lowering blood sugar. These drugs also provide cardiovascular and kidney protection beyond glucose control.
JARDIANCE Competitors
Pro10 other drugs also target SGLT2. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (SGLT2). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to JARDIANCE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
JARDIANCE FDA Label Details
ProIndications & Usage
FDA Label (PDF)JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. To reduce the risk of cardiovascular death in adult...
JARDIANCE Patents & Exclusivity
Patents (124 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.